Trial Details

Recruiting
Basic Information
Clinical ID c2267
Identifier IRCT20220409054467N3
Trial Title Effects of Adalimumab in Iranian Pediatric with Inflammatory Bowel Disease
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory bowel disease. Inflammatory polyps of colon with intestinal obstruction;K51.412
Interventions Intervention group: Administration of adalimumab (40 mg/0.8 ml) which is injected in patients weighing less than 40 kg based on the following dose: 80 mg first, 40 mg two weeks later, 20 mg two weeks after the second dose and then depending on the response, 20 mg should be taken subcutaneously once every one or two weeks. Also, subcutaneous injection was performed for people weighing more than 40 kg based on the following dose: first 160 mg, two weeks later 80 mg, two weeks after the second dose 40 mg, then according to the response, 40 mg is injected every one or two weeks..
Participant Information
Sponsor Tehran University of Medical Sciences
City -
Country/Region Iran
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, CHILD, TEENAGER
Study Design
Study Type interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -